On April 20, 2020, in response to COVID-19, CMS announced a new high-weighted COVID-19 Clinical Trials improvement activity for eligible clinicians who participate in the Quality Payment Program (QPP) under the Merit-based Incentive Payment System (MIPS). Eligible clinicians (which includes physicians, physician assistants, nurse practitioners, and others who participate in QPP) can receive credit for this improvement activity if they attest that they participate in a COVID-19 clinical trial utilizing a drug or biological product to treat a patient with a COVID-19 infection and report their findings through a clinical data repository or clinical data registry for the duration of their study. To read more about how to participate, read the CMS press release here. To read more about the QPP during the COVID-19 public health emergency, see the Quality Payment Program – COVID-19 Response Fact Sheet which is available here. To view a database of privately and publicly funded clinical studies currently being conducted on the corona virus click here. As we previously reported, CMS extended the MIPS mandatory data submission deadline until April 30, 2020.